tbuckley/cabot-search huggingface dataset:
Polyploidy formation in cancer cells: How a Trojan horse is born
Authors: Halina Was, Agata Borkowska, Aleksandra Olszewska, Aleksandra Klemba, Marta Marciniak, Agnieszka Synowiec, Claudine Kieda
Journal: Seminars in Cancer Biology (2021)

Ploidy increase has been shown to occur in different type of tumors and participate in tumor initiation and resistance to the treatment. Polyploid giant cancer cells (PGCCs) are cells with multiple nuclei or a single giant nucleus containing multiple complete sets of chromosomes. The mechanism leading to formation of PGCCs may depend on: endoreplication, mitotic slippage, cytokinesis failure, cell fusion or cell cannibalism. Polyploidy formation might be triggered in response to various genotoxic stresses including: chemotherapeutics, radiation, hypoxia, oxidative stress or environmental factors like: air pollution, UV light or hyperthermia. A fundamental feature of polyploid cancer cells is the generation of progeny during the reversal of the polyploid state (depolyploidization) that may show high aggressiveness resulting in the formation of resistant disease and tumor recurrence. Therefore, we propose that modern anti-cancer therapies should be designed taking under consideration polyploidization/ depolyploidization processes, which confer the polyploidization a hidden potential similar to a Trojan horse delayed aggressiveness. Various mechanisms and stress factors leading to polyploidy formation in cancer cells are discussed in this review.
P52.05 Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study).
Authors: V. Calvo, A. Ruano-Ravina, E. Carcereny, T. Moran, D. Rodríguez-Abreu, R. López-Castro, E. Cuadrado-Albite, M. Guirado, L. Gomez-Gonzalez, B. Massuti, A.L. Ortega Granados, A. Blasco, M. Cobo Dols, J. Mosquera, A. Hernandez-Martinez, J. Trigo, O. Juan, C. Aguado De La Rosa, M. Dómine Gómez, M. Sala, J. Oramas, C. Gonzalez Ojea, S. Cerezo, M. Provencio
Journal: Journal of Thoracic Oncology (2021)
P37.32 Epigenetic Imprinted Genes as Biomarkers for the Proactive Detection and Accurate Presurgical Diagnosis of Small Lung Nodules
Authors: N. Zhou, T. Cheng, X. Li, J. Zhou, M. Ding, J. Pineda, R. Shen, R. Yung, X. Wang, H. Si, P. Shi, C. Bai
Journal: Journal of Thoracic Oncology (2021)
Abstract P20: Continuity of oncology clinical trials during the Coronavirus Disease-2019 pandemic in Korea
Authors: Hee Kyung Ahn, Soohyeon Lee, Seon-A Jang, Ji-Yeon Kim, Jin Seok Ahn, Yeon Hee Park
Journal: Clinical Cancer Research (2021)

Abstract Coronavirus-19 outbreak caused concern of lowering performance of clinical trials, including delays in initiation, lower enrollment, or more frequent deviations related with visit schedule change. Korea, with the sixth largest number of industry-sponsored interventional drug trials in the world, has been controlling COVID-19 outbreak rather successfully and maintaining daily medical practice in most areas of the country. We investigated performance of oncology clinical trials before and after COVID-19 in Korea. We retrospectively identified and reviewed the files, notes, and source documents of ongoing breast cancer clinical trials during January to May 2019 and January to May 2020 in a single cancer center conducting oncology trials in Korea. Number of enrolled patients, drop-outs, protocol deviations including study visit delay or visit omission were measured. We investigated 77 ongoing studies from January to May 2020, and 67 from the same period in 2019. The numbers of newly initiated trials and new enrollment were not decreased during COVID-19 outbreak period. After outbreak of COVID-19, number of onsite monitoring was decreased, however total number of monitoring was maintained as remote monitoring was increased. Remote monitoring comprised 44% of all monitoring visit in 2020, and found 30%(15/50) of protocol deviations detected by all monitoring visit. Of the 26 study visit related protocol deviations during February to May 2020, 10(38%) cases were COVID-19 related. Thirteen percent(3/24) of study drop out cases were COVID-19 related, from subjects’ demand due to fear of visiting hospital. Although monitoring access was limited, vigorous countermeasures successfully maintained performance of oncology clinical trials during COVID-19 outbreak in Korea. Remote monitoring visits successfully complemented restricted onsite monitoring. COVID-19 related protocol deviations and drop-out cases were noted, mostly from subjects’ concerns about travel. Future regulations and guidelines should pursue developing alternatives of face-to-face contact visit as needed. Citation Format: Hee Kyung Ahn, Soohyeon Lee, Seon-A Jang, Ji-Yeon Kim, Jin Seok Ahn, Yeon Hee Park. Continuity of oncology clinical trials during the Coronavirus Disease-2019 pandemic in Korea [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2021 Feb 3-5. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(6_Suppl):Abstract nr P20.
P21.04 Comparing Outcomes for Patients Receiving Chemoradiation Followed by Surgery vs. Immune Checkpoint Inhibitors in Non Small Cell Lung Cancer
Authors: T. Chakrabarti, C. Friedes, S. Olson, L. Prichett, J. Brahmer, P. Forde, R. Voong, K. Marrone, V. Lam, C. Hann, S. Broderick, R. Battafarano, J. Ha, E. Bush, S. Yang, R. Hales, J. Feliciano
Journal: Journal of Thoracic Oncology (2021)
FOS/GOS attenuates high-fat diet induced bone loss via reversing microbiota dysbiosis, high intestinal permeability and systemic inflammation in mice
Authors: Zheng Zhang, Tao Lin, Yichen Meng, Miao Hu, Lun Shu, Heng Jiang, Rui Gao, Jun Ma, Ce Wang, Xuhui Zhou
Journal: Metabolism (2021)
Costs of Robotic-Assisted Radical Prostatectomy 1 Year After Surgery
Authors: Bogdana Schmidt, John T. Leppert
Journal: JAMA Network Open (2021)

Kennedy E. Okhawere, MD, MPH; I-Fan Shih, PhD; Shih-Hao Lee, MS; Yanli Li, PhD; Jaime A. Wong, MD, MBA; Ketan K. Badani, MD
OA01.03 Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
Authors: S. Kilickap, A. Sezer, M. Gümüş, I. Bondarenko, M. Özgüroğlu, M. Gogishvili, H.M. Turk, I. Cicin, D. Bentsion, O. Gladkov, P. Clingan, V. Sriuranpong, N. Rizvi, S. Li, S. Lee, T. Makharadze, S. Paydas, M. Nechaeva, F. Seebach, D.M. Weinreich, G.D. Yancopoulos, G. Gullo, I. Lowy, P. Rietschel
Journal: Journal of Thoracic Oncology (2021)
Long-Term Outcomes of Patients Undergoing the Ross Procedure
Authors: Anas Aboud, Efstratios I. Charitos, Buntaro Fujita, Ulrich Stierle, Jan-Christian Reil, Vladimir Voth, Markus Liebrich, Martin Andreas, Tomas Holubec, Constanze Bening, Marc Albert, Petr Fila, Jiri Ondrasek, Peter Murin, Rüdiger Lange, Hermann Reichenspurner, Ulrich Franke, Armin Gorski, Anton Moritz, Günther Laufer, Wolfgang Hemmer, Hans-Hinrich Sievers, Stephan Ensminger
Journal: Journal of the American College of Cardiology (2021)
Driving Impairment Following Vaporization of Cannabis
Authors: Jasvinder A. Singh
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P88.04 Successful Low-Dose Treatment for Patients with ROS1-Rearranged NSCLC who Developed Crizotinib-Related Heart Failure.
Authors: T. Hashimoto, K. Takahashi, S. Ota, N. Okumura, H. Kondo, A. Fukatsu, T. Hara
Journal: Journal of Thoracic Oncology (2021)
Reproducibility in machine learning for health research: Still a ways to go
Authors: Matthew B. A. McDermott, Shirly Wang, Nikki Marinsek, Rajesh Ranganath, Luca Foschini, Marzyeh Ghassemi
Journal: Science Translational Medicine (2021)

Machine learning for health must be reproducible to ensure reliable clinical use. We evaluated 511 scientific papers across several machine learning subfields and found that machine learning for health compared poorly to other areas regarding reproducibility metrics, such as dataset and code accessibility. We propose recommendations to address this problem.
Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing
Authors: Xi Gu, Daqi Wang, Zhijiao Xu, Jinghan Wang, Luo Guo, Renjie Chai, Genglin Li, Yilai Shu, Huawei Li
Journal: Genome biology (2021)

Abstract Background Aging, noise, infection, and ototoxic drugs are the major causes of human acquired sensorineural hearing loss, but treatment options are limited. CRISPR/Cas9 technology has tremendous potential to become a new therapeutic modality for acquired non-inherited sensorineural hearing loss. Here, we develop CRISPR/Cas9 strategies to prevent aminoglycoside-induced deafness, a common type of acquired non-inherited sensorineural hearing loss, via disrupting the Htra2 gene in the inner ear which is involved in apoptosis but has not been investigated in cochlear hair cell protection. Results The results indicate that adeno-associated virus (AAV)-mediated delivery of CRISPR/SpCas9 system ameliorates neomycin-induced apoptosis, promotes hair cell survival, and significantly improves hearing function in neomycin-treated mice. The protective effect of the AAV–CRISPR/Cas9 system in vivo is sustained up to 8 weeks after neomycin exposure. For more efficient delivery of the whole CRISPR/Cas9 system, we also explore the AAV–CRISPR/SaCas9 system to prevent neomycin-induced deafness. The in vivo editing efficiency of the SaCas9 system is 1.73% on average. We observed significant improvement in auditory brainstem response thresholds in the injected ears compared with the non-injected ears. At 4 weeks after neomycin exposure, the protective effect of the AAV–CRISPR/SaCas9 system is still obvious, with the improvement in auditory brainstem response threshold up to 50 dB at 8 kHz. Conclusions These findings demonstrate the safe and effective prevention of aminoglycoside-induced deafness via Htra2 gene editing and support further development of the CRISPR/Cas9 technology in the treatment of non-inherited hearing loss as well as other non-inherited diseases.
Food for thought: addressing undernutrition to end tuberculosis
Authors: Pranay Sinha, Knut Lönnroth, Anurag Bhargava, Scott K Heysell, Sonali Sarkar, Padmini Salgame, William Rudgard, Delia Boccia, Daniel Van Aartsen, Natasha S Hochberg
Journal: The Lancet Infectious Diseases (2021)
FP12.07 Prognostic Value of HLA-I Homozygosity in Non-Small Cell Lung Cancer Patients Treated with Single Agent Immunotherapy
Authors: A. Abed, L. Calapre, J. Lo, S. Correia, S. Bowyer, A. Chopra, M. Watson, M. Khattak, M. Millward, E. Gray
Journal: Journal of Thoracic Oncology (2021)
HSR21-041: Impact of Cardiac Comorbidities on Outcomes After Treatment for Locally Advanced Esophageal Cancer: An Institutional Experience
Authors: Luis Aguirre, Jacques Fontaine, Jessica Frakes, Sarah Hoffe, Jose Pimiento, Rutika Mehta
Journal: Journal of the National Comprehensive Cancer Network (2021)

"HSR21-041: Impact of Cardiac Comorbidities on Outcomes After Treatment for Locally Advanced Esophageal Cancer: An Institutional Experience" published on 17 Mar 2021 by National Comprehensive Cancer Network.
FP02.03 Changing Survival and Treatment Patterns in Patients Aged 80 or Older with Stage IV Non-Small Cell Lung Cancer (NSCLC)
Authors: M. Anaka, A. Gibson, M. Dean, A. Elegbede, L. Petersen, R. Tudor, R. Sangha, D.G. Bebb
Journal: Journal of Thoracic Oncology (2021)
心嚢液,胸水貯留で発症した悪性リンパ腫(Primary effusion lymphoma)の一例
Authors: 鷲尾武彦, 野本和幹, 榎本光信, 古川清隆, 佐藤喜洋, 小張力, 大場富哉, 渡辺郁能, 久代登志男
Journal: Circulation (2006)
Geometry encoded functional programming of tumor homing peptides for targeted drug delivery
Authors: Ruchika Goyal, Gaurav Jerath, R. Akhil, Aneesh Chandrasekharan, Eswara Rao Puppala, Srikanth Ponneganti, Anupam Sarma, V.G.M. Naidu, T.R. Santhoshkumar, Vibin Ramakrishnan
Journal: Journal of Controlled Release (2021)
Ventricular Arrhythmias Due to Glomangiosarcoma Cardiac Metastases
Authors: Chiara Lestuzzi, Giammaria Miolo, Lucia Tartuferi, Rosa Pecoraro, Antonino De Paoli, Ermanno Dametto, Nadir Sitta, Elisa Leiballi, Fabio D. Greco, Angela Buonadonna
Journal: JACC CardioOncology (2021)
P38.01 The Role of Pathology in The Proposed Subdivided N Descriptors of The TNM Staging System For Lung Cancer– A Single Center Experience
Authors: P. Bulutay, S. Erus, Ö. Yavuz, S. Çopur, E. Zeren, S. Tanju, Ş. Dilege, P. Fırat
Journal: Journal of Thoracic Oncology (2021)
P86.05 In Vitro Validation Study for HER2 Mutations Identified in Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial
Authors: A. Hamada, K. Suda, T. Fujino, M. Nishino, T. Koga, S. Ohara, M. Chiba, T. Takemoto, J. Soh, T. Mitsudomi
Journal: Journal of Thoracic Oncology (2021)
Abstract 275: Oxygen Weaning is Slow and Highly Variable Among Mechanically Ventilated Patients After Out-Of-Hospital Cardiac Arrest
Authors: Shaun K McGovern, Kemarut Laothamatas, Abhishek Bhardwaj, David G Buckler, Benjamin S Abella
Journal: Circulation (2019)

Introduction: Arterial hyperoxia at 6 h following resuscitation from out-of-hospital cardiac arrest (OHCA) may be associated with worsened survival and neurologic outcome. While global resuscitation guidelines call for prompt weaning of inhaled oxygen fraction (FiO2) following return of spontaneous circulation, with titration to oxygen saturation (SaO2) &gt;92%, the burden of hyperoxia (both FiO2 and duration) among OHCA patients in the emergency department (ED) and critical care setting is unknown. Objectives: We sought to characterize oxygen weaning behavior in a cohort of resuscitated and mechanically ventilated OHCA patients from two hospitals, with “hyperoxic exposure burden” defined as cumulative treatment hours with FiO2&gt;0.6. We hypothesized that the majority of these patients receive at least 6 h of hyperoxic exposure despite concomitant SaO2&gt;92% during and after weaning. Methods: A retrospective study of post-arrest care was performed at two academic hospitals from 1/2018-12/2018; both hospitals have well-developed post-arrest care protocols that include oxygen weaning instructions. Consecutive non-traumatic, adult (age&gt;17 y) OHCA patients treated in the emergency department that achieved sustained ROSC and received mechanical ventilation were included. Demographic data, as well as data on FiO2, SaO2 and arterial blood gas results, were collected for the first 24 h of post-arrest care. Results: 70 adult OHCA patients were included. Mean age was 61 y (SD 16.4), 51% were male, and 20% had initial shockable arrest rhythms. Survival to discharge was 21%. Median ED patient care time before ICU transfer was 2.7 h (IQR: 1.9-4.0). FiO2&gt;=0.6 was administered to 52% of the cohort for at least 6 h; the median duration of hyperoxic exposure burden was 8.7 h (IQR: 3.9-15.0) with a wide range from 0.6-92 h. Among all patients with 6 h or more with FiO2&gt;=0.6, median partial pressure of arterial oxygen was 136 mm Hg (IQR: 94-301) as measured during this period. Conclusions: Most resuscitated OHCA patients received substantial exposure to hyperoxia, and the timing of oxygen weaning was highly variable. Additional clinical investigation is required to understand the barriers to rapid weaning and to test the effect of improved weaning on clinical outcomes.
Abstract 2766: Diagnosis of Arrhythmogenic Right Ventricular Dysplasia with Endocardial Electroanatomic Mapping: Remote Magnetic Navigation Voltage Maps are More Accurate than Manual Maps
Authors: Philippe Ricard, Decebal G Latcu, Benedicte Godin, Khelil Yaici, Nadir Saoudi
Journal: Circulation (2008)

Electroanatomic endocardial mapping in arrhythmogenic right ventricular dysplasia (ARVD) using the CARTO™ system has shown to be useful in identifying low voltage areas as a marker of fatty infiltr...
P01.15 Immune-Related Adverse Effects of Immunotherapy in Patients With Advanced Non-Small Cell Lung Carcinoma
Authors: C. Freitas, F. Veiga, J. Costa, D. Araújo, H. Novais-Bastos, V. Santos, A. Magalhães, V. Hespanhol, H. Queiroga, G. Fernandes
Journal: Journal of Thoracic Oncology (2021)
Abstract 15886: Induced Pluripotent Stem Cell Derived Cardiomyocyte Exosomes Preserve Myocardial Viability and Reduce Negative Remodeling in a Porcine Model of Ischemia Reperfusion
Authors: Connor G Obrien, Yuko Tada, Michelle Santoso, Jennifer Lyons, Jihye Jung, Albert Jang, Evgeniya Vaskova, Phillip C Yang
Journal: Circulation (2019)

Introduction: Coronary artery disease is a leading cause of death worldwide. Ischemic injury leads to myocardial dysfunction, resulting in heart failure (HF) and ventricular arrhythmias. Exosomes h...
P58.02 Bronchial Field Progenitor Basal Cells Show Methylome-Wide Characteristics Reflective of Lung Cancer Case-Control, Age, and Smoking Status
Authors: K. Batbayar, K. Ye, S. Waldman, A. Marsh, M. Shi, T. Siddiqui, M. Suzuki, A. Desai, D. Patel, J. Patel, J. Dobkin, A. Sadoughi, C. Shah, P. Yakov, J. Vijig, S. Spivack
Journal: Journal of Thoracic Oncology (2021)
DNAJC30 biallelic mutations extend mitochondrial complex I–deficient phenotypes to include recessive Leber’s hereditary optic neuropathy
Authors: Janey L. Wiggs
Journal: Journal of Clinical Investigation (2021)

Leber's hereditary optic neuropathy (LHON) is the most common mitochondrial disease and in most cases is caused by mutations in mitochondrial DNA–encoded (mtDNA-encoded) respiratory complex I subunit ND1, ND4, or ND6. In this issue of the JCI, Stenton et al. describe biallelic mutations in a nuclear DNA–encoded gene, DNAJC30, establishing recessively inherited LHON (arLHON). Functional studies suggest that DNAJC30 is a protein chaperone required for exchange of damaged complex I subunits. Hallmark mtDNA LHON features were also found in arLHON, including incomplete penetrance, male predominance, and positive response to idebenone therapy. These results extend complex I–deficient phenotypes to include recessively inherited optic neuropathy, with important clinical implications for genetic counseling and therapeutic considerations.
The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors
Authors: Sung-Eun Lee, Won-Sik Lee, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, Young Rok Do, Jae-Yong Kwak, Sukjoong Oh, Sung-Hyun Kim, Jeong-A Kim, Dae Young Zang, Yeung-Chul Mun, Young-Woong Won, Dong-Wook Kim
Journal: Blood (2017)
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer
Authors: Andrea Ardizzoni, Sergio Azevedo, Belen Rubio-Viqueira, Delvys Rodríguez-Abreu, Jorge Alatorre-Alexander, Hans J M Smit, Jinming Yu, Konstantinos Syrigos, Kerstin Trunzer, Hina Patel, Jonathan Tolson, Andres Cardona, Pablo D Perez-Moreno, Tom Newsom-Davis
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Atezolizumab treatment improves survival, with manageable safety, in patients with previously treated advanced/metastatic non-small cell lung cancer. The global phase III/IV study TAIL ( NCT03285763 ) was conducted to evaluate the safety and efficacy of atezolizumab monotherapy in a clinically diverse population of patients with previously treated non-small cell lung cancer, including those not eligible for pivotal trials. Methods Patients with stage IIIB/IV non-small cell lung cancer whose disease progressed after 1–2 lines of chemotherapy were eligible for this open-label, single-arm, multicenter study, including those with severe renal impairment, an Eastern Cooperative Oncology Group performance status of 2, prior anti-programmed death 1 (PD-1) therapy, and autoimmune disease. Atezolizumab was administered intravenously (1200 mg every 3 weeks). Coprimary endpoints were treatment-related serious adverse events and immune-related adverse events. Results 619 patients enrolled and 615 received atezolizumab. At data cutoff, the median follow-up was 12.6 months (95% CI 11.9 to 13.1). Treatment-related serious adverse events occurred in 7.8% and immune-related adverse events in 8.3% of all patients and as follows, respectively, in these subgroups: renal impairment (n=78), 11.5% and 12.8%; Eastern Cooperative Oncology Group performance status of 2 (n=61), 14.8% and 8.2%; prior anti–PD-1 therapy (n=39), 5.1% and 7.7%; and autoimmune disease (n=30), 6.7% and 10.0%. No new safety signals were reported. In the overall population, the median overall survival was 11.1 months (95% CI 8.9 to 12.9), the median progression-free survival was 2.7 months (95% CI 2.1 to 2.8) and the objective response rate was 11%. Conclusions This study confirmed the benefit–risk profile of atezolizumab monotherapy in a clinically diverse population of patients with previously treated non-small cell lung cancer. These safety and efficacy outcomes may inform treatment decisions for patients generally excluded from checkpoint inhibitor trials.